- Home
- KEY vs GMAB Comparison
KEY vs GMAB Comparison
Compare KEY & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEY
- GMAB
- Stock Information
- Founded
- KEY 1825
- GMAB 1999
- Country
- KEY United States
- GMAB Denmark
- Employees
- KEY N/A
- GMAB N/A
- Industry
- KEY Major Banks
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KEY Finance
- GMAB Health Care
- Exchange
- KEY Nasdaq
- GMAB Nasdaq
- Market Cap
- KEY 20.8B
- GMAB 17.4B
- IPO Year
- KEY N/A
- GMAB N/A
- Fundamental
- Price
- KEY $18.09
- GMAB $32.69
- Analyst Decision
- KEY Buy
- GMAB Strong Buy
- Analyst Count
- KEY 16
- GMAB 7
- Target Price
- KEY $20.41
- GMAB $41.17
- AVG Volume (30 Days)
- KEY 26.9M
- GMAB 2.2M
- Earning Date
- KEY 10-16-2025
- GMAB 11-05-2025
- Dividend Yield
- KEY 4.54%
- GMAB N/A
- EPS Growth
- KEY N/A
- GMAB 77.72
- EPS
- KEY 0.03
- GMAB 21.62
- Revenue
- KEY $4,743,000,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- KEY $76.60
- GMAB $24.25
- Revenue Next Year
- KEY $6.10
- GMAB $16.29
- P/E Ratio
- KEY $566.19
- GMAB $1.51
- Revenue Growth
- KEY N/A
- GMAB 32.97
- 52 Week Low
- KEY $12.73
- GMAB $17.24
- 52 Week High
- KEY $20.04
- GMAB $33.63
- Technical
- Relative Strength Index (RSI)
- KEY 39.12
- GMAB 79.00
- Support Level
- KEY $18.35
- GMAB $28.36
- Resistance Level
- KEY $19.04
- GMAB $33.63
- Average True Range (ATR)
- KEY 0.38
- GMAB 0.61
- MACD
- KEY -0.07
- GMAB 0.22
- Stochastic Oscillator
- KEY 0.54
- GMAB 83.93
About KEY KeyCorp
With assets of around $185 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.